Publications
5803 Results
- Journal / Conference
- Cancer Sep 1;130(17):2918-2927
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID38358334
- PMC
- PMC11309904
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 48) in Patients with Advanced Gallbladder Cancer
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 3; abstr 726); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA, poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
Diversity of Patients Enrolled in SWOG Gastrointestinal Cancers Therapeutic Trials
- Journal / Conference
- Prostate Cancer and Prostatic Diseases Feb 29. doi: 10.1038/s41391-024-00813-3. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38424319
- Study Number(s)
- S1216
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel [Brief Report]
- Journal / Conference
- European Urology Oncology Oct;7(5):1097-1104
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38523017
- Study Number(s)
- S1216
Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide
- Journal / Conference
- Cancer. 2024 Jul 1;130(13):2384-2394. doi: 10.1002/cncr.35264. Epub 2024 Feb 22.
- Year
- 2024
- Research Committee(s)
- Palliative Care
- PMID
- PMID38386696
- PMC
- PMC11162313
- Study Number(s)
- S1820
SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer
- Journal / Conference
- ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in metastatic colorectal cancer (mCRC) patients (pts)
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 4; abstr 509)
- Year
- 2024
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S1823
North American Patterns of Care in Clinical Stage I Testicular Cancer. Secondary Data Use Project for SWOG S1823
- Journal / Conference
- JCO Oncology Practice Apr;20(4):491-502
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID38252911
- PMC
- PMC11085951
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 3; abstr TPS430); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), TIP, poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S2303
SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
- Journal / Conference
- ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA); J Clin Oncol 42, 2024 (suppl 3; abstr 664), poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021501